Glutamate transporter GLAST/EAAT1 directs cell surface expression of FXYD2/γ subunit of Na, K-ATPase in human fetal astrocytes
Introduction
Glutamic acid, a major excitatory amino acid in the brain, at higher concentrations can trigger aberrant metabolic pathways leading to neurodegeneration. The excess of extracellular glutamate is normally neutralized by high-affinity uptake mechanism executed by a family of glutamate transporter proteins: GLAST/EAAT1, GLT1/EAAT2, EAAC1/EAAT3, EAAT4 and EAAT5. The energy source for these secondary carriers is the electrochemical Na+ gradient maintained by Na+, K+-ATPase (Kanai and Hediger, 1992, Pines et al., 1992, Storck et al., 1992, Fairman et al., 1995, Arriza et al., 1997; for more references, see Gegelashvili and Schousboe, 1997, Gegelashvili and Schousboe, 1998, Gegelashvili et al., 2001, Danbolt, 2001).
In some pathological conditions (e.g. amyotrophic lateral sclerosis, ischemia, neurotrauma), this system fails to catch up with gradually increasing load of glutamate either because of the reduced expression of glutamate transporter proteins or due to the sustained alterations in ionic environment affecting kinetic properties of glutamate carriers. Moreover, as a result of severe cell energy deficit, glutamate transporters instead of protecting neurons, can aggravate excitotoxic insult by releasing intracellular glutamate through the reversed mode of operation (Choi, 1994, Rothstein et al., 1995, Rossi et al., 2000, Bonde et al., 2003a, for more references, see Yi and Hazell, 2006, Danbolt, 2001, Gegelashvili et al., 2001).
The major site for glutamate uptake in the brain is astroglia (Schousboe, 1981). Translocation of glutamate across the astroglial plasma membrane is executed by two distinct glutamate transporter subtypes, GLAST/EAAT1 and GLT1/EAAT2. Due to the emergence of the astroglial transport system as an obvious therapeutic target, molecular and cellular regulation of GLAST and GLT1 have been extensively studied in recent years (Gegelashvili et al., 1996, Gegelashvili et al., 1997, Gegelashvili et al., 2000, Swanson et al., 1996, Trotti et al., 1999, Zelenaia et al., 2000, Figiel et al., 2003, Rodriguez-Kern et al., 2003, Bonde et al., 2003b; see more references in Gegelashvili et al., 2001). Binding and subsequent translocation of glutamate into the cytosolic compartment by these two astroglial transporters serve both removal of the excess of glutamate from the perisynaptic space and nutritional supply of astrocytes. At the same time, elevated glutamate uptake dramatically increases energy demands of astrocytes, primarily due to ATP-consuming conversion of glutamate into glutamine as well as increased activity of Na+, K+-ATPase (Pellerin and Magistretti, 1994, Pellerin and Magistretti, 1997). The mechanism of glutamate uptake-dependent stimulation of the astroglial sodium pump has been explained by increased net influx of Na+ through glutamate transporter(s) (Magistretti and Chatton, 2005). Although it has been proposed that functional up-regulation of the catalytic α2 subunit of Na, K-ATPase is responsible for this effect (Pellerin and Magistretti, 1997), no experimental data on the roles of distinct molecular components of the sodium pump in this process have been provided so far. In the present study, we demonstrate that the activity of glutamate transporter GLAST/EAAT1 can effectively regulate cell surface expression of the γ subunit (FXYD2) of Na+, K+ ATPase in human fetal astrocytes.
Section snippets
Materials
TFB-TBOA was synthesized at Suntory Institute for Bioorganic Research. Biotinylation kit, including sulfo-NHS-biotin and immunopure immobilized monomeric avidin was purchased from Pierce (Rockford, IL, USA). Metabotropic glutamate receptor antagonists: MPEP hydrochloride (for mGluR5), YM298198 (for mGluR1), LY341495 (for group II mGluRs), CPPG (for group III mGluRs), AMPA/kainate selective glutamate receptor anatgonist: CNQX disodium salt, NMDA receptor antagonist: norketamine hydrochloride
Results and discussion
The undifferentiated human fetal astroglial cultures expressed only one member of the high-affinity glutamate transporter family, GLAST/EAAT1, in agreement with our previous data obtained with primary neonatal rodent astrocytes (Gegelashvili et al., 1996, Gegelashvili et al., 1997, Gegelashvili et al., 2000, Gegelashvili et al., 2006). We took advantage of this fact to elucidate roles of GLAST in the modulation of Na+, K+-ATPase activity.
In control cultures with extracellular concentration of
Acknowledgements
The expert secretarial assistance of Ms. Tea Gobronidze, as well as the expert technical assistance of Maria Lopez Casta is cordially acknowledged. Authors would like to thank Rockwell Research Fund for financial support.
References (33)
- et al.
Neurotoxic and neuroprotective effects of the glutamate transporter inhibitor DL-threo-beta-benzyloxyaspartate (TBOA) during physiological and ischemia-like conditions
Neurochem. Int.
(2003) - et al.
GDNF pre-treatment aggravates neuronal cell loss in oxygen-glucose deprived hippocampal slice cultures: a possible effect of glutamate transporter upregulation
Neurochem. Int.
(2003) Glutamate receptors and the induction of excitotoxic neuronal death
Prog. Brain Res.
(1994)Glutamate uptake
Prog. Neurobiol.
(2001)- et al.
Regulation of glial glutamate transporter expression by growth factors
Exp. Neurol.
(2003) - et al.
Cellular distribution and kinetic properties of high-affinity glutamate transporters
Brain Res. Bull.
(1998) - et al.
The high-affinity glutamate transporters GLT1, GLAST, and EAAT4 are regulated via different signalling mechanisms
Neurochem. Int.
(2000) - et al.
Regulation of glutamate transporters in health and disease
Prog. Brain Res.
(2001) - et al.
High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes
Neuochem. Int.
(2006) - et al.
Na, K-ATPase from mice lacking the γ subunit (FXYD2) exhibits altered Na+ affinity and decreased thermal stability
J. Biol. Chem.
(2005)